Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Debuts US Symbicort Rival

Following Legal Wrangling, Breyna Launched In US With Partner Kindeva

Executive Summary

Years after introducing the first US generic version of Advair, Viatris is leading the way on another respiratory launch with Breyna, the first US rival to Symbicort.

You may also be interested in...



Stick, Twist Or Split? Generics Industry’s Big Three Place Their Bets

With Teva and Viatris recently under new management and Sandoz having last year split from former parent company Novartis, the three off-patent industry leaders are adopting different strategies for how they balance their generics and biosimilars interests with more innovative ventures.

A Year Of Change: Viatris Ploughs Ahead With Brand Ambitions

In 2024, Viatris will initiate the second phase of its long-term business plan, which will see it step away from the perceived volatility of the generics space and begin to move toward innovative and high-growth products. The past year has seen it lay the groundwork for this pivot, shedding surplus business units and making significant hires from the branded space.

Cipla Readies gSymbicort, Semaglutide Amid Sale Speculation ‘Distraction’

Cipla’s US business scales new peak in Q2 amid strong showing overall even as the promoter group stake sale speculation is becoming a 'distraction'. The company has new peptide assets, among others, in the wings while management also points to traction in the 'mRNA journey'.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel